Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis

• DOI: 10.18632/oncotarget.3269
• Publication Date: 2015-09-15T07:00:46Z
• Authors: Sébastien Tabariès; Matthew G. Annis; Brian E. Hsu; Christine E. Tam; Paul Savage; Morag Park; Peter M. Siegel
• Keywords: LYN

// Sébastien Tabariès 1, 2 , Matthew G. Annis Brian E. Hsu Christine Tam Paul Savage Morag Park 2, 3, 4 Peter M. Siegel 3 1 Goodman Cancer Research Centre, McGill University, Montréal, Québec, Canada, H3A 1A3 Department of Medicine, Biochemistry, Oncology, Correspondence to: Siegel, e-mail: [e-mail] Keywords: breast cancer, liver metastasis, claudins, Src family kinase, Lyn Received: January 26, 2015      Accepted: 31, Published: March 25, 2015 ABSTRACT Claudin-2 enhances cancer metastasis and promotes the development colorectal cancers. The objective our current study is to define regulatory mechanisms controlling expression in cells. We evaluated effect several Family Kinase (SFK) inhibitors or knockdown individual SFK members on also assessed potential effects pan-SFK SFK-selective formation metastases. This reveals that pan inhibition signaling pathways significantly elevated levels In addition, data demonstrate can enhance liver. Knockdown loss Yes Fyn induces expression; whereas, diminished impairs Lyn-selective kinase inhibitor, Bafetinib (INNO-406), acts reduce suppress metastasis. Our findings may have major clinical implications advise against treatment patients with broad-acting support use Lyn-specific inhibitors.